Abstract
The treatment of advanced and metastatic gastrointestinal stromal tumours (GIST) has been revolutionised by the development of the drug imatinib mesylate (Glivec), one of the first targeted molecular therapies available for the treatment of cancer. However, little has been previously documented about this rare tumour. The aim of this article is to provide an overview of GIST and its treatment, and discuss the nursing management of GIST patients. This is particularly timely given that the National Institute for Clinical Excellence is expected to publish its guidance for the use of Glivec in the treatment of unresectable and/or metastatic GISTs this September.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
